Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333011 | 0.84 | CTSL (0.53) | P2RX7CCR1CTSLCTSBCTSS | |
| SCHEMBL4973030 | 0.83 | P2RX7 (0.54) | P2RX7CTSLCTSS | |
| SCHEMBL11257246 | 0.81 | TACR1 (0.63) | P2RX7TGM2CTSLCTSBCTSS | |
| SCHEMBL11257249 | 0.81 | TACR1 (0.63) | P2RX7TGM2CTSLCTSBCTSS | |
| SCHEMBL9819722 | 0.81 | ITGB3 (0.52) | TGM2 | |
| SCHEMBL30101252 | 0.80 | SYK (0.48) | CTSLCTSBCTSSCTSK | |
| SCHEMBL28811676 | 0.79 | ATM (0.54) | CCR1CTSLCTSBCTSSCTSK | |
| SCHEMBL4976037 | 0.78 | P2RX7 (0.43) | P2RX7TGM2CTSLCTSBCTSS | |
| SCHEMBL953169 | 0.78 | TSHR (0.51) | P2RX7TGM2CTSLCTSBCTSS | |
| SCHEMBL953167 | 0.78 | TSHR (0.51) | P2RX7TGM2CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | ZIKANI THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4358970-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | Zikani Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022251730-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | ZIKANI THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | UPF1, RRP1B, REV1 | P2RX7 4079/4885CCR1 4439/4885TGM2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.